EP2630498A4 - Prognostic biomarkers in patients with ovarian cancer - Google Patents
Prognostic biomarkers in patients with ovarian cancerInfo
- Publication number
- EP2630498A4 EP2630498A4 EP11835211.1A EP11835211A EP2630498A4 EP 2630498 A4 EP2630498 A4 EP 2630498A4 EP 11835211 A EP11835211 A EP 11835211A EP 2630498 A4 EP2630498 A4 EP 2630498A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- patients
- ovarian cancer
- prognostic biomarkers
- prognostic
- biomarkers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
- G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/416—Systems
- G01N27/447—Systems using electrophoresis
- G01N27/44756—Apparatus specially adapted therefor
- G01N27/44773—Multi-stage electrophoresis, e.g. two-dimensional electrophoresis
- G01N27/44778—Multi-stage electrophoresis, e.g. two-dimensional electrophoresis on a common gel carrier, i.e. 2D gel electrophoresis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/54—Determining the risk of relapse
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40604410P | 2010-10-22 | 2010-10-22 | |
| PCT/US2011/057271 WO2012054824A2 (en) | 2010-10-22 | 2011-10-21 | Prognostic biomarkers in patients with ovarian cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP2630498A2 EP2630498A2 (en) | 2013-08-28 |
| EP2630498A4 true EP2630498A4 (en) | 2014-10-01 |
Family
ID=45975910
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP11835211.1A Ceased EP2630498A4 (en) | 2010-10-22 | 2011-10-21 | Prognostic biomarkers in patients with ovarian cancer |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP2630498A4 (en) |
| JP (2) | JP2013541716A (en) |
| AU (1) | AU2011316844A1 (en) |
| CA (1) | CA2818593A1 (en) |
| WO (1) | WO2012054824A2 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2914918C (en) * | 2013-05-10 | 2023-10-10 | Johns Hopkins University | Compositions and methods for ovarian cancer assessment having improved specificity |
| JP6019254B2 (en) * | 2014-04-23 | 2016-11-02 | 株式会社ニチレイバイオサイエンス | Target marker detection combination |
| EP3435379A1 (en) * | 2017-07-27 | 2019-01-30 | Roche Diagnostics GmbH | Augmenting measurement values of biological samples |
| WO2019088709A2 (en) * | 2017-10-31 | 2019-05-09 | 국립암센터 | Information providing method for predicting ovarian cancer prognosis by using nc886 gene |
| JP7272627B2 (en) * | 2019-01-24 | 2023-05-12 | 公立大学法人和歌山県立医科大学 | Biomarkers for evaluation of ovarian tumors |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008048508A2 (en) * | 2006-10-13 | 2008-04-24 | Vermillion, Inc. | Prognostic biomarkers in patients with ovarian cancer |
| WO2009058331A2 (en) * | 2007-10-29 | 2009-05-07 | Vermilllion, Inc. | Biomarkers for the detection of early stage ovarian cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101692090B (en) * | 2002-08-06 | 2014-06-25 | 约翰霍普金斯大学 | Use of biomarkers for detecting ovarian cancer |
| EP2199801B1 (en) * | 2004-07-14 | 2013-05-29 | The Regents of The University of California | Biomarkers for early detection of ovarian cancer |
| CA2602088C (en) * | 2005-03-11 | 2021-07-27 | Ciphergen Biosystems, Inc. | Biomarkers for ovarian cancer and endometrial cancer |
| WO2007002527A2 (en) * | 2005-06-24 | 2007-01-04 | Ciphergen Biosystems, Inc. | BIOMARKERS FOR OVARIAN CANCER: β-2 MICROGLOBULIN |
| WO2008060376A2 (en) * | 2006-10-04 | 2008-05-22 | The Johns Hopkins University | Algorithims for multivariant models to combine a panel of biomarkers for assessing the risk of developing ovarian cancer |
| CA2691980C (en) * | 2007-06-29 | 2022-05-10 | Correlogic Systems, Inc. | Predictive markers for ovarian cancer |
| JP5391400B2 (en) * | 2007-10-01 | 2014-01-15 | 公益財団法人ヒューマンサイエンス振興財団 | Method for assisting detection of pancreatic cancer using copy number or expression level of α-actinin-4 gene as an index and kit for diagnosis |
| US8632984B2 (en) * | 2009-02-16 | 2014-01-21 | Atlas Antibodies Ab | RBM3 as a marker for malignant melanoma prognosis |
-
2011
- 2011-10-21 JP JP2013535113A patent/JP2013541716A/en active Pending
- 2011-10-21 EP EP11835211.1A patent/EP2630498A4/en not_active Ceased
- 2011-10-21 WO PCT/US2011/057271 patent/WO2012054824A2/en active Application Filing
- 2011-10-21 CA CA2818593A patent/CA2818593A1/en not_active Abandoned
- 2011-10-21 AU AU2011316844A patent/AU2011316844A1/en not_active Abandoned
-
2016
- 2016-08-04 JP JP2016153332A patent/JP2016212116A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008048508A2 (en) * | 2006-10-13 | 2008-04-24 | Vermillion, Inc. | Prognostic biomarkers in patients with ovarian cancer |
| WO2009058331A2 (en) * | 2007-10-29 | 2009-05-07 | Vermilllion, Inc. | Biomarkers for the detection of early stage ovarian cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012054824A2 (en) | 2012-04-26 |
| AU2011316844A1 (en) | 2013-06-06 |
| EP2630498A2 (en) | 2013-08-28 |
| CA2818593A1 (en) | 2012-04-26 |
| WO2012054824A3 (en) | 2012-07-19 |
| JP2013541716A (en) | 2013-11-14 |
| JP2016212116A (en) | 2016-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL252163A0 (en) | Lung cancer biomarkers and uses thereof | |
| EP2536854A4 (en) | Personalized tumor biomarkers | |
| IL223295A0 (en) | Lung cancer biomarkers and uses thereof | |
| EP2382331A4 (en) | Cancer biomarkers | |
| SG10201710447QA (en) | Pancreatic cancer biomarkers and uses thereof | |
| EP2825674A4 (en) | Thyroid cancer biomarker | |
| EP2776832A4 (en) | Biomarkers for bladder cancer and methods using the same | |
| HK1206414A1 (en) | Biomarkers for gastric cancer and uses thereof | |
| HK1181846A1 (en) | Novel biomarkers and targets for ovarian carcinoma | |
| EP2625292A4 (en) | Biomarkers of cancer | |
| GB2513275B (en) | Biomarkers for Breast Cancer Prediction and Diagnosis | |
| EP2931922A4 (en) | Personalized biomarkers for cancer | |
| GB2513771B (en) | Biomarkers for breast cancer predictions and diagnoses | |
| GB201021502D0 (en) | Biomarkers | |
| GB201008340D0 (en) | Biomarkers | |
| EP2600896A4 (en) | Treating breast cancer with anti-il-19 antibody | |
| GB201018056D0 (en) | Biomarkers | |
| EP2630498A4 (en) | Prognostic biomarkers in patients with ovarian cancer | |
| GB201005561D0 (en) | Biomarkers | |
| GB201001444D0 (en) | Biomarkers | |
| EP2350917A4 (en) | Ovarian cancer biomarkers and uses thereof | |
| EP2554994A4 (en) | Biomarkers | |
| GB201010316D0 (en) | Biomarkers | |
| GB201005456D0 (en) | Biomarkers | |
| GB201004304D0 (en) | Biomarkers for prostate cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20130521 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20140901 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: G01N 33/543 20060101ALI20140826BHEP Ipc: G01N 33/574 20060101AFI20140826BHEP Ipc: G01N 30/00 20060101ALI20140826BHEP Ipc: G01N 33/68 20060101ALI20140826BHEP |
|
| 17Q | First examination report despatched |
Effective date: 20150904 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R003 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
| 18R | Application refused |
Effective date: 20161104 |